One Week of Magnesium Supplementation Lowers IL-6, Perceived Pain and Increases Post Exercise Blood Glucose in Response to Downhill Running

January 1, 2020 updated by: Charles Steward, University of Worcester
This study investigated the effect of magnesium supplementation on exercise performance and functional recovery in recreational endurance athletes in conjunction with measures of blood glucose, lactate, IL-6 and sIL-6R.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

Magnesium status can directly affect circulating glucose concentrations both during and post exercise. In addition, magnesium supplementation has been shown to reduce circulating IL-6 concentrations post exercise in humans. It is conceivable that such observations are linked through the role of IL-6 in glucose regulation, possibly in combination with sIL-6R. Together, magnesium intake may have the potential to effect exercise performance and recovery through glucose availability. This in turn may be connected to the production of IL-6 and sIL-6R which have been established to influence exercise fatigue and perception of pain (muscle soreness).

Study Type

Interventional

Enrollment (Actual)

9

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • United Kingdom
    • Worcestershire
      • Worcester, Worcestershire, United Kingdom, WR1 3AS
        • University of Worcester

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

20 years to 35 years (ADULT)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

Male

Description

Inclusion Criteria:

  • Regular recreational runner, running around 3 times per week
  • Capable of running 10 km in ~ 40 minutes.

Exclusion Criteria:

  • Any signs or symptoms of cardiovascular issues.
  • Any recent form of injury or illness.
  • Currently, or in the last 3 months, have consumed multivitamin supplements
  • Currently, or in the last 3 months, have consumed anti-inflammatory medications.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: PREVENTION
  • Allocation: RANDOMIZED
  • Interventional Model: CROSSOVER
  • Masking: DOUBLE

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
EXPERIMENTAL: High magnesium diet (SUP condition)
Participants followed a low magnesium diet <260mg/day and consumed 500 mg/day of magnesium oxide. This was separated into 3 capsules, which were consumed at 6 hr intervals each day (8am, 2pm and 8pm). The supplementation period was 1 week.
Dietary supplement: Magnesium oxide
Magnesium capsule
EXPERIMENTAL: Low magnesium diet (CON condition)
Participants followed a low magnesium diet <260mg/day and consumed 500 mg/day of placebo (cornflour). This was separated into 3 capsules, which were consumed at 6 hr intervals each day (8am, 2pm and 8pm). The supplementation period was 1 week.
Dietary supplement: Placebo
Cornflour capsule manufactured to mimic the 166.6 mg magnesium capsule.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Downhill 10 km treadmill time trial performance
Time Frame: 1 day
Maximal 10 km time trial performance on a treadmill
1 day
24 hr post exercise maximal force testing of the dominant leg on the isokinetic dynamometer
Time Frame: 1 day
Maximal force produced from the dominant leg (eccentric and concentric) on an isokinetic dynamometer.
1 day

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Glucose
Time Frame: up to 2 days
Capillary blood samples at rest, during, immediately post, 1 hr post and 24 hrs post 10 km downhill time-trial. A Biosen analyser was used to analyse glucose concentrations.
up to 2 days
Interleukin-6
Time Frame: up to 2 days
Venous blood samples at rest, immediately post, 1hr post and 24 hrs 10 km downhill time trial. Enzyme-linked immunosorbent assays were used to analyse interleukin-6.
up to 2 days
Soluble interleukin-6 receptor
Time Frame: up to 2 days
Venous blood samples at rest, immediately post, 1hr post and 24 hrs 10 km downhill time trial. Enzyme-linked immunosorbent assays were used to analyse soluble interleukin-6.
up to 2 days
Perceived muscle soreness
Time Frame: up to 4 days
A 10cm visual analogue scale was used to assess perceived muscle soreness, the scale started at 0 (no pain) and finished at 10 (unbearable pain)
up to 4 days
Lactate
Time Frame: up to 2 days
Capillary blood samples at rest, during, immediately post, 1 hr post and 24 hrs post 10 km downhill time-trial. A Biosen analyser was used to analyse lactate concentrations.
up to 2 days
Creatine kinase
Time Frame: up to 2 days
Venous blood samples at rest, immediately post, 1hr post and 24 hrs 10 km downhill time trial. A Reflotron analyser was used to analyse creatine kinase concentrations.
up to 2 days

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

University of Worcester

Collaborators

Coventry University
Beijing Sport Uninversity

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (ACTUAL)

June 28, 2018

Primary Completion (ACTUAL)

March 1, 2019

Study Completion (ACTUAL)

March 1, 2019

Study Registration Dates

First Submitted

September 17, 2019

First Submitted That Met QC Criteria

January 1, 2020

First Posted (ACTUAL)

January 3, 2020

Study Record Updates

Last Update Posted (ACTUAL)

January 3, 2020

Last Update Submitted That Met QC Criteria

January 1, 2020

Last Verified

January 1, 2020

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • SH17180029-R

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Magnesium Deficiency

Clinical Trials on Magnesium oxide

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Guinea

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe